{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T20:54:43Z","timestamp":1788900883123,"version":"build-2803163510"},"reference-count":10,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T00:00:00Z","timestamp":1667865600000},"content-version":"vor","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPGN rep."],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:sec><jats:label\/><jats:p>Dupilumab is approved for the treatment of eosinophilic esophagitis (EoE). We report a teenager with difficult\u2010to\u2010treat EoE on topical corticosteroids (TS) who achieved clinical and histological remission when initiated on dupilumab for a primary indication of atopic dermatitis. However, when his TS were weaned after achieving remission, his disease relapsed with worsening of his dysphagia and a peak eosinophilic count (PEC) of 55 eosinophils per high power field (eos\/hpf). Upon restarting TS to his ongoing dupilumab, symptoms fully resolved, and he achieved histologic remission (PEC 10 eos\/hpf). This report underscores the: (1) importance of longitudinal monitoring for EoE patients on dupilumab, (2) unmet need for guidance on how to transition EoE patients on traditional therapies to dupilumab, and (3) need for longitudinal follow\u2010up data on dupilumab to help personalize therapy for EoE patients.<\/jats:p><\/jats:sec>","DOI":"10.1097\/pg9.0000000000000273","type":"journal-article","created":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T21:00:08Z","timestamp":1675112408000},"source":"Crossref","is-referenced-by-count":6,"title":["Relapse of Eosinophilic Esophagitis on Dupilumab"],"prefix":"10.1002","volume":"3","author":[{"given":"Matthew A.","family":"Buendia","sequence":"first","affiliation":[{"name":"Division of Pediatric Gastroenterology, Hepatology and Nutrition Department of Pediatrics Vanderbilt University Medical Center Nashville TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yash A.","family":"Choksi","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Hepatology and Nutrition Department of Medicine Vanderbilt University Medical Center Nashville TN"},{"name":"Tennessee Valley Health System Veterans Affairs Nashville TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Girish","family":"Hiremath","sequence":"additional","affiliation":[{"name":"Division of Pediatric Gastroenterology, Hepatology and Nutrition Department of Pediatrics Vanderbilt University Medical Center Nashville TN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,11,8]]},"reference":[{"key":"e_1_2_4_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1502863"},{"key":"e_1_2_4_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-015-3723-8"},{"key":"e_1_2_4_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.14920"},{"key":"e_1_2_4_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2017.202"},{"key":"e_1_2_4_6_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.09.052"},{"key":"e_1_2_4_7_1","unstructured":"U.S. Food and Drug Administration.FDA Approves First Treatment for Eosinophilic Esophagitis a Chronic Immune Disorder.https:\/\/www.fda.gov\/news\u2010events\/press\u2010announcements\/fda\u2010approves\u2010first\u2010treatment\u2010eosinophilic\u2010esophagitis\u2010chronic\u2010immune\u2010disorder. Accessed June 6 2022. [Press release]."},{"key":"e_1_2_4_8_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.09.042"},{"key":"e_1_2_4_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.12.347"},{"key":"e_1_2_4_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/PG9.0000000000000180"},{"key":"e_1_2_4_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2022.01.043"}],"container-title":["JPGN Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1097\/PG9.0000000000000273","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T14:48:19Z","timestamp":1749739699000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1097\/PG9.0000000000000273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["10.1097\/PG9.0000000000000273"],"URL":"https:\/\/doi.org\/10.1097\/pg9.0000000000000273","archive":["Portico"],"relation":{},"ISSN":["2691-171X","2691-171X"],"issn-type":[{"value":"2691-171X","type":"print"},{"value":"2691-171X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11]]},"article-number":"e273"}}